...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Message: Price for Phase 1 Alz drug

 "The drug was evaluated before the spin-off in two Phase 1A clinical trials that yielded positive safety results but no data on efficacy."

so they paid 75 million upfront followed by milestone payments for a P1a drug that only yielded safety results but no efficacy data??

Good grief and here we sit, with a ton of data showing efficacy in numerous indications and a fantastic safety profile, and all the company can do at this point is discount some warrants to raise cash......DM needs to go....

New Message
Please login to post a reply